Antimicrobial Resistance Mitigation For Novel Anti-Infective Agents During the Preclinical Drug Development Stage
“As sure as the sun will rise tomorrow, so will emergence of resistance to new anti-infective agents. It is as sure as the seasons. It is the force of evolution itself.”
Antimicrobial Resistance Mitigation
Praediacre houses several of the Infectious Diseases Physicians, Public Health experts, and mathematical modelers who pioneered the techniques, methods, and skills to allow the approaches described here to effect AMR emergence mitigation.
At Praedicare, we recognize that the emergence of antimicrobial resistance [AMR] to novel drugs is an integral part of the life cycle of that agent once approved for clinical use by drug regulating agencies, with dire global health consequences. Therefore, we developed a specific program to mitigate that, to predict that, and to diagnose that, even before drug gets to the clinic. We have developed a step-by-step approach, and the necessary SOPs, to help biotech companies develop antimicrobials access this process. This includes antibacterial agents, antiviral agents, antiparasitic agents, and antifungal agents. Out output includes optimal dosing strategies and identification of key companion drugs to mitigate AMR emergence, development of diagnostic kits to identify the resistance, and the solutions to apply when the resistance is eventually identified. We do not try to stand in the way of the river of evolution, but we intend to help clients and their products ride it smoothly and dodge the waterfalls, long before they get to the river.
At Praedicare we also work with hospital antibiotic stewardship committees using mathematical models and simulations-based on hospital quarterly data to predict antibiotic resistance patterns in subsequent quarters, and patients’ demographics, organism isolate whole genome sequences, and human population genetics, to develop an antibiotic selection and dosing strategy specific to the health center. We can model and forecast the evolution of resistance in the future based on the past, using mathematics and wet lab tools. We give antibiotic stewardship committees tools to deal with AMR, and to foresee it.
At Praedicare we also work with hospital systems, states, and countries, using mathematical models and simulations-based on hospital system or country level data quarterly and yearly data to predict antibiotic resistance patterns in subsequent quarters. We incorporate country population pharmacokinetics, the population’s genetics, whole genome sequencing for the top 10 organisms, and our wet lab tools to develop an antibiotic selection and dosing strategy specific to the hospital system and country. We can model and forecast the evolution of resistance in the future based on the past, using mathematics and wet lab tools at Praedicare. We give countries and health systems policy tools to deal with AMR, and to foreknow future patterns of AMR.